(Street)

(City)

DALLAS

TX

(State)

1. Name and Address of Reporting Person*

75201

(Zip)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden
hours per response: 0.5

Instruction	1(b).	366	Filed	d pursuant t							1934		nours per re	esponse:	0.5	
1. Name and Address of Reporting Person* <u>Ikarian Capital, LLC</u>				2. Issue	or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol Tracon Pharmaceuticals, Inc. [TCON]							Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner				
(Last) (First) (Middle) 100 CRESCENT COURT, SUITE 1620					3. Date of Earliest Transaction (Month/Day/Year) 09/04/2020							Officer (give title X Other (specify below) Member of 10% Group				
(Street) DALLAS TX 75201			4. If Am	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting					
(City)	(St	ate)	(Zip)									Perso	on			
			e I - Non-Deriv			1	quir				_	-		1		
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired Disposed Of (D) (Instr		r. 3, 4 and 5) SB OFF R		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	٧	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)				
Common Stock, par value \$0.001 per share			09/04/2020			P		151,61	1 A	\$2.86	559(1)	1,991,689	I	See footnotes ⁽²⁾ (3)(4)(5)		
Common Stock, par value \$0.001 per share			09/08/2020			P		13,244	I A	\$2.9		2,004,933	2,004,933 I		See footnotes ⁽²⁾ (3)(4)(5)	
per share			09/09/2020					79,415	5 A	\$3.4938		2,084,348	I	See foot (3)(4)(5)		
Common Stock, par value \$0.001 per share 09/11/2020				P			78,201		A \$3.926		2,162,549	I	I See footnotes ⁽²⁾			
		T	able II - Deriva (e.g., p	itive Sec outs, call									t			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year	ion X/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 8) 4. Transaction Code (Instr. 8) 5. Number of Expiration Date (Month/Day/Year) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. A Scurifies Acquired (A) or Scurifies Scurifies Acquired (A) or Scurifies Scurifies Scurifies Scurifies Acquired (A) or Scurifies Scurifies Scurifies Scurifies Acquired (A) or Scurifies Scurifi		7. Titl Amou Secur Unde Deriv Secur 3 and	int of rities rlying ative rity (Insti	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)						
				Code V	. (4	A) (D)	Dat Exc	te ercisable	Expiration Date	Title	Amount or Number of Shares	r				
	nd Address of Capital,	Reporting Perso	n [*]			·	•									
(Last) 100 CRE		(First) OURT, SUITE	(Middle) 1620													
(Street) DALLA	S	TX	75201													
(City)		(State)	(Zip)													
		Reporting Perso are Master F														
(Last)		(First) OURT, SUITE	(Middle)													

Shahrestani	hrestani Neil							
(Last)	(First)	(Middle)						
100 CRESCENT COURT, SUITE 1620								
(Street)								
DALLAS	TX	75201						
(City)	(State)	(Zip)						

Explanation of Responses:

- 1. This price represents the approximate weighted average price per share of common stock of TRACON Pharmaceuticals, Inc., a Delaware corporation (the "Issuer"), par value \$0.001 per share ("Shares"), of purchases that were executed at prices ranging from \$2.7981 to \$2.9986 per Share. The Reporting Persons undertake to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the price per Share and the number of Shares purchased at each price.
- 2. This statement is jointly filed by and on behalf of each of Ikarian Capital, LLC, a Delaware limited liability company ("Ikarian Capital"), Ikarian Healthcare Master Fund, L.P, a Cayman Islands exempted limited partnership (the "Fund"), Ikarian Healthcare Fund GP, L.P., a Delaware limited partnership ("Ikarian GP"), Chart Westcott and Neil Shahrestani (collectively referred herein as the "Reporting Persons"). Ikarian Capital is the investment manager of, and may be deemed to indirectly beneficially own securities owned by, the Fund. Ikarian GP is the general partner of, and may be deemed to indirectly beneficially own securities owned by, the Fund. Ikarian GP is the general partner of, and may be deemed to indirectly beneficially own, securities beneficially owned by Ikarian GP.
- 3. Ikarian Capital is a sub-advisor for certain separate managed accounts (collectively, the "Managed Accounts") and may be deemed to indirectly beneficially own securities owned by the Managed Accounts. Ikarian Capital is ultimately owned and controlled by Chart Westcott Living Trust, of which Mr. Westcott serves as the sole trustee (the "Trust"), and indirectly by Mr. Shahrestani. Accordingly, each of Mr. Westcott, as sole trustee of the Trust, and Mr. Shahrestani may be deemed to indirectly beneficially own securities beneficially owned by, Ikarian Capital. The Fund and the Managed Accounts are the record and direct beneficial owners of the securities covered by this statement. The Fund disclaims beneficial ownership of the shares held by the Managed Accounts.
- 4. The Reporting Persons state that neither the filing of this statement nor anything herein shall be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any securities covered by this statement. The Reporting Persons disclaim beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of the Reporting Persons in such securities.
- 5. The Reporting Persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for purposes of Section 13(d) or 13(g) of the Exchange Act. The Reporting Persons declare that neither the filing of this statement nor anything herein shall be construed as an admission that such persons are, for the purposes of Section 13(d) or 13(g) of the Exchange Act or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer.

Remarks

IKARIAN CAPITAL, LLC By: Chart Westcott Living Trust Its: Manager By: /s/ Chart Westcott Chart Westcott, Trustee	09/15/2020
IKARIAN HEALTHCARE MASTER FUND, L.P. By: Ikarian Healthcare Fund GP, L.P. Its: General Partner By: Ikarian Capital, LLC Its: General Partner By: Chart Westcott Living Trust Its: Manager By: /s/ Chart Westcott Chart Westcott, Trustee	09/15/2020
IKARIAN HEALTHCARE FUND GP, L.P. By: Ikarian Capital, LLC Its: General Partner By: Chart Westcott Living Trust Its: Manager By: /s/ Chart Westcott Chart Westcott, Trustee	09/15/2020
CHART WESTCOTT LIVING TRUST By: /s/ Chart Westcott Chart Westcott, Trustee	09/15/2020
NEIL SHAHRESTANI /s/ Neil Shahrestani	09/15/2020
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.